Iteos Financial Statements From 2010 to 2026
| ITOSDelisted Stock | USD 10.15 0.00 0.00% |
Check Iteos Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Iteos Therapeutics' main balance sheet or income statement drivers, such as , as well as many indicators such as . Iteos financial statements analysis is a perfect complement when working with Iteos Therapeutics Valuation or Volatility modules.
Iteos |
Iteos Therapeutics Company Current Valuation Analysis
Iteos Therapeutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Iteos Therapeutics Current Valuation | (61.62 M) |
Most of Iteos Therapeutics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Iteos Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, Iteos Therapeutics has a Current Valuation of (61.62 Million). This is 100.43% lower than that of the Biotechnology sector and 101.33% lower than that of the Health Care industry. The current valuation for all United States stocks is 100.37% higher than that of the company.
Iteos Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Iteos Therapeutics's current stock value. Our valuation model uses many indicators to compare Iteos Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Iteos Therapeutics competition to find correlations between indicators driving Iteos Therapeutics's intrinsic value. More Info.Iteos Therapeutics is rated fourth overall in return on equity category among its peers. It also is rated fourth overall in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Iteos Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.About Iteos Therapeutics Financial Statements
Iteos Therapeutics shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Iteos Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Iteos Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Iteos Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts. Iteos Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 94 people.
Thematic Opportunities
Explore Investment Opportunities
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Other Consideration for investing in Iteos Stock
If you are still planning to invest in Iteos Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Iteos Therapeutics' history and understand the potential risks before investing.
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Stocks Directory Find actively traded stocks across global markets |